GeneTherapy Market is projected to grow at an annualized rate of 45%, till 2030
Encouragingclinical results across various metabolic, hematological and ophthalmicdisorders have inspired research groups across the world to focus their effortson the development of novel gene editing therapies. In fact, the gene therapypipeline has evolved significantly over the past few years, with three productsbeing approved in 2019 alone; namely Beperminogene perplasmid (AnGes),ZOLGENSMA® (AveXis) and ZYNTEGLO™ (bluebird bio).
Further, there are multiple pipeline candidates in mid tolate-stage (phase II and above) trials that are anticipated to enter the marketover the next 5-10 years.
TheUSD 11.6 billion (by 2030) financial opportunity within the Gene Therapy Markethas been analyzed across the following segments:
ReadDetailed Report: https://www.rootsanalysis.com/reports/view_document/gene-therapies-market/268.html
Keytherapeutic areas
· Autoimmune disorders
· Cardiovascular diseases
· Genetic disorders
· Hematological disorders
· Metabolic disorders
· Ophthalmic disorders
· Oncological disorders
· Others
Typeof vector
· Adeno associated virus
· Adenovirus
· Herpes simplex virus type 1
· Lentivirus
· Plasmid DNA
· Retrovirus
· Vaccinia Virus
Typeof therapy
· Ex vivo
· In vivo
Typeof gene modification
· Gene augmentation
· Immunotherapy
· Oncolytic therapy
· Others
Routeof administration
· Intraarticular
· Intracerebellar
· Intramuscular
· Intradermal
· Intravenous
· Intravitreal
· Intravesical
· Subretinal
· Others
Keygeographical regions
· North America
· Europe
· Asia-Pacific
GetDetailed Sample Report: https://www.rootsanalysis.com/reports/268/request-sample.html
TheGene Therapy Market (3rd Edition), 2019-2030 report features the followingcompanies, which we identified to be key players in this domain:
· Advantagene
· Advaxis
· BioMarin
· bluebird bio
· FKD Therapies
· Freeline Therapeutics
· GenSight Biologics
· Gradalis
· Inovio Pharmaceuticals
· Marsala Biotech
· Orchard Therapeutics
· Pfizer
· Sarepta Therapeutics
· Spark Therapeutics
· Tocagen
· Transgene
· uniQure Biopharma
· VBL Therapeutics
· ViroMed
ChapterOutline
Chapter2provides an executive summary of the key insights captured in our research. Itoffers a high-level view on the current state of the market for gene therapiesand its likely evolution in the short-mid term and long term.
Chapter3provides a general overview of gene therapies, including a discussion on theirhistorical background. It further highlights the different types of genetherapies (namely somatic and germline therapies, and in vivo and ex vivotherapies), potential application areas of such products and route ofadministration of these therapeutic interventions. In addition, it providesinformation on the concept of gene editing, highlighting key historicalmilestones, applications and various techniques used for gene editing. The alsochapter includes a discussion on the advantages and disadvantages associatedwith gene therapies. Further, it features a brief discussion on the ethical andsocial concerns related to gene therapies, while highlighting futureconstraints and challenges related to the manufacturing and commercial viabilityof such product candidates.
Chapter4provides a general introduction to the various types of viral and non-viralgene delivery vectors. It includes a detailed discussion on the design,manufacturing requirements, advantages and limitations of currently availablevectors.
Chapter5features a detailed discussion on the regulatory landscape related to genetherapies across various geographies, such as the US, Canada, Europe,Australia, China, Hong Kong, Japan and South Korea. Further, it highlights anemerging concept of reimbursement which was recently adopted by multiple genetherapy developers, along with a discussion on several issues associated with reimbursementof gene therapies.
Chapter6includes information on over 800 gene therapies and gene editing therapies thatare currently approved or are in different stages of development. It features adetailed analysis of pipeline molecules, based on several relevant parameters,such as key therapeutic areas (autoimmune disorders, cardiovascular diseases,dermatological disorders, genetic disorders, hematological disorders,immunological disorders, infectious diseases, inflammatory disorders, liverdiseases, metabolic disorders, muscle-related diseases, nervous systemdisorders, oncological disorders, ophthalmic diseases and others), targetdisease indication(s), phase of development (marketed, clinical, preclinicaland discovery), type of vector used, type of gene, type of gene therapy (exvivo and in vivo), therapeutic approach (gene augmentation, oncolytic viraltherapy and others), route of administration and special drug designation (ifany). Further, we have presented a grid analysis of gene therapies based onphase of development, therapeutic area and therapeutic approach.
Chapter7provides a detailed review of the players engaged in the development of genetherapies, along with information on their year of establishment, company size,location of headquarters, regional landscape and key players engaged in thisdomain. Further, we have presented a logo landscape of product developers inNorth America, Europe and the Asia-Pacific region on the basis of company size.
Chapter8provides detailed profiles of marketed gene therapies. Each profile includesinformation about the innovator company, its product pipeline (focused on genetherapy only), development timeline of the therapy, its mechanism of action,target indication, current status of development, details related tomanufacturing, dosage and sales, the company’s patent portfolio andcollaborations focused on its gene therapy product / technology.
Chapter9features an elaborate discussion on the various strategies that can be adoptedby therapy developers across key commercialization stages, including prior todrug launch, during drug launch and post-launch. In addition, it presents anin-depth analysis of the key commercialization strategies that have been adoptedby developers of gene therapies approved during the period 2015-2020.
Chapter10provides detailed profiles of drugs that are in advanced stages of clinicaldevelopment (phase II/III and above). Each drug profile provides information onthe current developmental status of the drug, its route of administration,developers, primary target indication, special drug designation received,target gene, dosage, mechanism of action, technology, patent portfolio,clinical trials and collaborations (if any).
Requestfor Customization:
https://www.rootsanalysis.com/reports/268/request-customization.html
Covid-19Update – Explore our latest Reports
NovelT-Cell Immunotherapies Market
GlycosylationAnalysis Services Market
CRISPRBased Therapeutics Market
DisplayLibrary Technologies and Affiliated Services Market
AboutRoots Analysis
RootsAnalysis is one of the fastest growing marketresearch companies, sharing fresh and independent perspectives in thebio-pharmaceutical industry. The in-depth research, analysis and insights aredriven by an experienced leadership team which has gained many years ofsignificant experience in this sector. If you’d like help with your growingbusiness needs, get in touch at info@rootsanalysis.com
ContactInformation
RootsAnalysis Private Limited
GauravChaudhary
+1(415) 800 3415
